UNDIAGNOSED: Medical Refugees (Feature Length Medical Documentary)
While searching for her own allusive diagnosis, a prominent psychologist discovers a hidden epidemic of undiagnosed patients drowning in the healthcare system. She is presented with a rare opportunity to bring worldwide attention to their struggle, and decides to help them unite in this powerful story of desperation, heartache, and ultimately, hope.
Interome was founded by Harris & Harris Group, Inc., during the first quarter of 2016. Interome's goal is to combine multiple types of genotypic, phenotypic and physiological information on a platform that acts as the engine to organize, integrate, interpret and create interoperability between the consumer and the different requirements that exist within the clinical setting. Interome focuses on the markets of undiagnosed disease and elite athletic training and is working with top researchers and clinicians, as well as companies such as Metabolon, ORIG3N, Genomic Profiling, and Muses Labs, to provide information that can aid undiagnosed disease patients and athletes.
Katia Moritz, Ph.D., ABPP
Dr. Katia Moritz is a psychologist in the States of Florida and Utah and is Board Certified in Cognitive and Behavioral Psychology. She is the co-founder and Clinical Director of the NeuroBehavioral Institute and has dedicated her life to treating severe and debilitating anxiety disorders in children and adults. In August of 2010 Dr. Moritz underwent a routine endoscopy and woke up with an unknown syndrome. After seeing doctors all over the country at various facilities, she is still undiagnosed. In her search for help, she encountered a world of patients and families that were struggling with all of the same issues. The glaring need to foster awareness has inspired her to do something to initiate change. She created the feature length documentary, "Undiagnosed: Medical Refugees," based on the stories of these patients, their doctors and the medical system that is failing to service them.
Crystal Shearman is the co-founder and executive producer at Crowbait Pictures, a boutique production company based in Park City, Utah and Vancouver, Canada. Since 2008 Crowbait Pictures has specialized in developing startup productions in formats ranging from short films, web series and music videos, to television pilots and feature films. Crystal’s current project is the feature length documentary Undiagnosed: Medical Refugees. This groundbreaking film exposes a global healthcare crisis of millions of sick children and adults who suffer for many years, even lifetimes, without a diagnosis. Through the fascinating, personal stories of six different families, Undiagnosed explores why the medical system is failing this population and how studying these patients will advance medicine for all of humanity.
Ryan J. Taft, Ph.D.
Illumina is a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, it enables its customers to read and understand genetic variations. Illumina strives to make its solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.
Dr. Ryan Taft is the Director, Scientific Research, at Illumina, Inc., with a focus on the development and deployment of diagnostic whole genome sequencing worldwide, particularly for patients with rare and undiagnosed genetic diseases. He obtained his BS in Biochemistry and Molecular Biology from the University of California, Davis on a Regent’s Scholarship, and his Ph.D. in Genomics and Computational Biology from the University of Queensland on a U.S. National Science Foundation Research Fellowship. He was previously a Group Leader & Senior Research Fellow at the University of Queensland, where he still holds a minor appointment, and he is Adjunct Associate Professor at the George Washington University School of Medicine and Health Sciences. He has published in a variety of well-regarded journals, including articles in Nature Genetics, Nature Structural and Molecular Biology, the American Journal of Human Genetics, and others. He is a founding member of the Global Leukodystrophy Initiative and is delighted to help drive solutions for patients with rare diseases through Global Genes.
Douglas W. Jamison
Doug Jamison is Chairman and CEO of Harris & Harris Group, Inc., a publicly traded venture capital company listed on the Nasdaq Global Market (NASDAQ: TINY). Harris & Harris Group builds transformative companies enabled by disruptive science. He has previously held the positions of President, COO and CFO of Harris & Harris Group, Inc. He is Chairman of the Board of Directors of HZO, Inc., ProMuc, Inc., and Interome, Inc., as well as a member of the Board of Directors of ORIG3N, Inc., and TARA Biosystems, Inc., privately held portfolio companies of Harris & Harris Group in the precision medicine market. He is Co-Editor-in-Chief of "Nanotechnology Law & Business." He was a member of the University of Pennsylvania Nano-Bio Interface Ethics Advisory Board. Prior to joining Harris & Harris Group, he was a Senior Technology Manager at the University of Utah Technology Transfer Office.